MYND Life Sciences Inc (MYND)

MYND, 10Q due Dec 12

MYND.......................https://stockcharts.com/h-sc/ui?s=MYND&p=W&b=5&g=0&id=p86431144783

MYND..........................https://stockcharts.com/h-sc/ui?s=MYND&p=W&b=5&g=0&id=p86431144783

MYND: New 52 HIGH.

_____________________________________________________________________
I'm producing a film, "American Cars of 1908" --- tap link below for latest edition:
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExOXVyb2N1NXVkejE5em04cDMyYnRvbDV2ejAzeHdsdmZzc2JxajQwZSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/f1NTdkdbG4XzW/giphy.gif

MYND new 52 low

Beat up pre market but seems ok now

$MYNDF MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
Press Release | 12/15/2021
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
PR Newswire

VANCOUVER, BC, Dec. 15, 2021

VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: "A Method of Immune Modulation by Modulating a Specific Gene."

Mynd Life Sciences logo (CNW Group/Mynd Life Sciences Inc.)

"MYND's is profoundly different than the majority of the Psychedelics' sector. We are seeking intellectual property protection through the pursuit of patents by validation of our Intellectual Property through research and development," stated Dr. Lyle Oberg, MD, CEO of MYND. "As this sector grows and matures and as MYND develops our novel drug development pipeline, the creation of a solid intellectual property portfolio is the key to creating lasting shareholder value. MYND's ability to obtain patent protection will allow us to move towards the filing of Innovative New Drug (IND) application and approval status."

According to the World Health Organization, over 300,000,000 people globally suffer from depression and other psychiatric disorders. Major Depressive Disorder and Treatment Resistant Depression have a greater than 50% chance of relapse using conventional methods of treatment. Traditional treatments focus solely on symptom suppression, not the root cause. Covid-19 has accelerated the ongoing mental health crisis around the world. In a June 2020 CDC survey, 31% of US respondents reported symptoms of anxiety or depression, 13% started/increased substance use, 26% reported stress-related symptoms, 11% reported serious thoughts of suicide in preceding 30 days. These numbers are double pre-pandemic levels.

The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent offices in what is called the "national phase". https://www.uspto.gov/patents/basics/international-protection/patent-cooperation-treaty

MYND MARKETING AND INVESTOR RELATIONS AGREEMENTS

MYND has retained Hybrid Financial Ltd. ("Hybrid") to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for MYND and to broaden it's reach within the biotech drug research and development investment community. Hybrid has been engaged for a monthly fee of $22,500 by the Company for an initial period of twelve months, commencing November 16, 2021.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mynd-life-sciences-provides-update-on-depression-gene-modulation-pathway-patent-application-301445299.html

$MYNDF MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
Press Release | 12/15/2021
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
PR Newswire

VANCOUVER, BC, Dec. 15, 2021

VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: "A Method of Immune Modulation by Modulating a Specific Gene."

Mynd Life Sciences logo (CNW Group/Mynd Life Sciences Inc.)

"MYND's is profoundly different than the majority of the Psychedelics' sector. We are seeking intellectual property protection through the pursuit of patents by validation of our Intellectual Property through research and development," stated Dr. Lyle Oberg, MD, CEO of MYND. "As this sector grows and matures and as MYND develops our novel drug development pipeline, the creation of a solid intellectual property portfolio is the key to creating lasting shareholder value. MYND's ability to obtain patent protection will allow us to move towards the filing of Innovative New Drug (IND) application and approval status."

According to the World Health Organization, over 300,000,000 people globally suffer from depression and other psychiatric disorders. Major Depressive Disorder and Treatment Resistant Depression have a greater than 50% chance of relapse using conventional methods of treatment. Traditional treatments focus solely on symptom suppression, not the root cause. Covid-19 has accelerated the ongoing mental health crisis around the world. In a June 2020 CDC survey, 31% of US respondents reported symptoms of anxiety or depression, 13% started/increased substance use, 26% reported stress-related symptoms, 11% reported serious thoughts of suicide in preceding 30 days. These numbers are double pre-pandemic levels.

The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent offices in what is called the "national phase". https://www.uspto.gov/patents/basics/international-protection/patent-cooperation-treaty

MYND MARKETING AND INVESTOR RELATIONS AGREEMENTS

MYND has retained Hybrid Financial Ltd. ("Hybrid") to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for MYND and to broaden it's reach within the biotech drug research and development investment community. Hybrid has been engaged for a monthly fee of $22,500 by the Company for an initial period of twelve months, commencing November 16, 2021.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mynd-life-sciences-provides-update-on-depression-gene-modulation-pathway-patent-application-301445299.html

Nice

It's too bad that people on the yahoo board trashed this stock and sold before the record date to receive the dividend.

This is a firm commitment offering of 1,400,000 shares of our common stock, par value $0.001 per share. It is currently estimated that the public offering price will be between $5.50 and $6.50 per share.

https://www.sec.gov/Archives/edgar/data/1771077/000121390019018216/fs12019a2_telemyndinc.htm

See news...

https://finance.yahoo.com/news/emmaus-life-sciences-completes-merger-225100145.html

Hmmm halted?

I bought in for the spin-off, hope it works out. We will see Thursday. Let's see what the share price brings tomorrow,

MYND ANALYTICS STOCK PRICE COULD DOUBLE

INVESTORS ARE REWARDED FOR LOYALTY WITH MAJOR STOCK MOVES ON MERGER CLARITY
Yutaka Niihara, MD , MPH, CEO and Chairman of Emmaus, stated, "We are very grateful for this opportunity to merge with MYnd Analytics . The anticipated listing on Nasdaq via the merger with MYnd Analytics is an important step to maximize value for shareholders. We look forward to sharing with the public markets our progress on the market acceptance of Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. Endari addresses a $3 billion global market. In addition to the treatment of sickle cell disease, we believe our platform technology has the potential to address other major clinical indications such as diverticulosis."

Robin Smith, Chairman of MYnd Analytics , commented, "We are pleased with the progress of the merger and spin-off transaction, which remains on track to close before the end of this month, subject to approval of shareholders. We believe this transaction will drive significant value for all shareholders, and we will provide further updates following the respective shareholder meetings."

AVERAGE ANALYSTS PRICE TARGET $4
AVERAGE ANALYSTS RECOMMENDATION BUY

COMPANY PROFILE
MYnd Analytics , Inc. operates as a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. It provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioural disorders, includes depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. The company was founded by Leonard J. Brandt and Brain McDonald on March 20, 1987 and is headquartered in Aliso Viejo, CA.

Dawson James Securities 7/10 research report. $4 target.

https://files.constantcontact.com/fdcb5758701/58a94bf0-5b84-4cda-9dc9-efde7780e174.pdf

Emmaus Life Sciences to Go Public Via Merger


In a filing with the Securities and Exchange Commission, Emmaus disclosed revenues of $14.5 million in 2018, with a forecast of $45.2 million in revenues this year, growing to a projected $246.6 million by 2023.


http://labusinessjournal.com/news/2019/jul/11/torrance-based-emmaus-life-sciences-become-publicl/

yesterday seems to be exit of fast $$$... the outside day in MYND many times is a precursor to higher volatility... which with the spin-off and closing next monday kinda makes sense.

Interesting

MYnd Analytics and Emmaus Life Sciences Report Progress on Merger and Spin-off Transaction

Merger and Spin-off Transaction on Track to Close by End of July

New Spin-Off Record Date Set for July 15, 2019

MISSION VIEJO, Calif. and TORRANCE, Calif., July 09, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (Nasdaq: MYND) , a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, today provided an update on the planned merger and spin-off transaction announced on January 7, 2019. The respective special stockholder meetings will be held today, July 9, 2019, to consider approval of the proposed merger and spin-off transaction. Subject to approval by holders of record of the companies at the respective special stockholder meetings, MYnd will issue a number of shares of common stock to the current Emmaus shareholders, which will result in MYnd shareholders retaining 5.9% of the fully diluted shares of the 'New Emmaus' post-closing and a pro rata distribution of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The companies have set a new Spin-Off Record Date of July 15, 2019 in order to comply with certain NASDAQ and DTC requirements. Those individuals who hold shares at the close of trading on the 16th of July will receive the Telemynd dividend. MYnd shares will trade ex-dividend on July 17, which means that persons who purchase MYnd shares on July 17 will not receive shares of Telemynd.

It is expected that on July 16 and July 17, the necessary steps will occur to spin off Telemynd with the current MYnd assets, effectuate the merger and any adjustments needed to meet NASDAQ listing standards and commence trading on July 18, 2019 under the new symbol “EMMA.”

Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus, stated, “We are very grateful for this opportunity to merge with MYnd Analytics. The anticipated listing on Nasdaq via the merger with MYnd Analytics is an important step to maximize value for shareholders. We look forward to sharing with the public markets our progress on the market acceptance of Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. Endari addresses a $3 billion global market. In addition to the treatment of sickle cell disease, we believe our platform technology has the potential to address other major clinical indications such as diverticulosis.”

Robin Smith, Chairman of MYnd Analytics, commented, “We are pleased with the progress of the merger and spin-off transaction, which remains on track to close before the end of this month, subject to approval of shareholders. We believe this transaction will drive significant value for all shareholders, and we will provide further updates following the respective shareholder meetings.”

http://www.globenewswire.com/news-release/2019/07/09/1880221/0/en/MYnd-Analytics-and-Emmaus-Life-Sciences-Report-Progress-on-Merger-and-Spin-off-Transaction.html

I’ve only got MYND-

nice timing! out of curiosity, did you buy the MYND or the warrants, MYNDW? it seems the news that MYND is lowering the strike of MYNDW from $5.25 to $2.00 makes the warrants substantially more valuable than they were, with HUGE leverage should MYND really take off.

MYND VOTE TO APPROVE EMMAUS MERGER TUESDAY 7/9!

Emmaus Life Sciences has a FDA approved drug for Sickle Cell disease, Endari. This will be followed by MYND spinning off their telepsychiatry/AI PEER 4.0 device into a newly formed NASDAQ listed company, TeleMYnd...

In doing some research it seems the market opportunity for Sickle Cell is quite large and expected to more than double in the next four years.

Sickle Cell market size $2.1B growing to $4.5B by 2025. Also Emmaus is listed as the #1 key player!


here is the study...
https://www.marketwatch.com/press-release/sickle-cell-anemia-therapeutics-market-size-to-surge-at-110-cagr-and-hit-usd-4500-million-by-2025-2019-04-09

MYND VOTE 7/9 on Emmaus Life Sciences reverse merger!

found this article was posted from 2017 entitled, "Mystery biotech Emmaus grabs groundbreaking FDA panel backing for sickle cell drug — after quietly scrapping $225M deal"

here is the link;
https://endpts.com/mystery-biotech-emmaus-grabs-a-big-win-as-fda-experts-endorse-sickle-cell-drug-right-after-scrapping-a-225m-deal/

it seems Emmaus scrapped the deal when it was apparent the FDA was going to approve Endari, the Sickle Cell Disease drug. probably because Emmaus mgmt knew they were worth more. so what's Emmaus worth now?

according to this Sickle Cell research article the Sickle Cell market size is $2.1B, growing to $4.5B by 2025. the article also list the key players. Emmaus is first on the list;

The key players covered in this study:
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals

here is a link to the article

https://t.co/DOPy4WBRtS

considering we are not even talking about the Telepsychiatry and PEER 4.0 AI device here, MYND's market cap seems to be extremely cheap.

Got a few smacks here. I’m in

MYND warrants MYNDW amended strike price from $5.25 to $2.00!

On June 28, 2019, the Company amended the terms of its existing Warrant Agreements, dated as of July 19, 2017 and July 25, 2017, which were entered into between the Company and American Stock Transfer & Trust Company, as warrant agent (the “Warrant Agreements”), to reduce the exercise price of the warrants issued pursuant to the Warrant Agreements from $5.25 to $2.00 per share, effective upon the consummation of the Merger, for a period of one year.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=12988570&ds=2

MYND released investor presentation today. but you are right it is quiet here. i used to post the news but figured i'll just keep accumulating and ppl will know about the reverse merger with Emmaus Life Sciences, with approved Sickle Cell drug Endari. Or the telepsychiatry angle combined with the PEER device for benefiting mental health patients. The presentation shows that the PEER device has an addressable market of $42B! the FDA have already designated it with breakthrough device status so approval is being fast tracked. ppl will find it all out soon enough.

here is a link to the presentation...

https://www.sec.gov/Archives/edgar/data/822370/000121390019011087/f8k061819ex99-1_mynd.htm

Quiet here?

$MYND Tomorrow could be a big day, after hours action again


On Thursday the company announced that certain investors have agreed to purchase approximately $2.8 million of the Company’s common stock in a registered direct offering. The stock had a run but the weakness in the market it sonon pulled back. When we get a good day in the market keep a watch on this stock for a monster move on high volume .

The Company entered into a securities purchase agreement with the investors pursuant to which the Company agreed to sell 2,776,491 shares of its common stock at a per share price of $1.02. The closing of the registered direct offering is expected to take place on or about May 28, 2019, subject to the satisfaction of customary closing conditions.
Average Analysts Price Target $4
Average recommendation Buy

GREAT NEWS FOR MYND!!

Access to telehealth services for seniors got another boost Friday when the Centers for Medicare & Medicaid Services said it would allow private Medicare Advantage plans to offer additional access to virtual doctors in their basic benefit packages.

"This is a bold and important move by CMS, signaling to the rest of the healthcare system that telehealth based care is simply another form of care and should be treated as such,” MDLive’s chief medical officer and executive vice president of product strategy, Dr. Lyle Berkowitz said. “This is a rare win for providers, patients and payors.”

https://www.forbes.com/sites/brucejapsen/2019/04/06/more-telehealth-benefits-coming-to-medicare-advantage-plans-in-2020/#27eecbd12712

MYnd Analytics Webinar Replay...

MYND holding investor call to update recent developments....


holding the call on April 4 @ 11:00 am EST....
https://www.redchip.com/events/40/MYnd-Analytics-Webinar

Robert Plotkin, Chief Executive Officer and Founder of Arcadian, will present a company overview at 2019 Telemed Leadership Forum, entitled, “Transforming Healthcare Delivery,” on Thursday, April 4th at 3:30pm ET followed by a panel discussion entitled, “Models of Tele-Behavioral Health Services,” on Thursday April 4th at 4:15pm ET. Mr. Plotkin plans to discuss how technology is being used to improve behavioral healthcare and reduce overall costs to the healthcare system.

MYND could be in the news later this week...

https://finance.yahoo.com/news/ceo-arcadian-telepsychiatry-services-invited-131500913.html

MYnd Analytics Awarded European Patent on Neuromodulation Platform; Predicts Patients Likely to Respond to TMS for Treating Depression

https://finance.yahoo.com/news/mynd-analytics-awarded-european-patent-132000591.html

North Dakota doesn’t have enough psychiatrists. Telemedicine is helping to fix that.

MYND the only public play in telepsychiatry!

https://www.statnews.com/2019/03/28/telemedicine-psychiatry-north-dakota/

CEO of Arcadian Telepsychiatry Services Invited by URAC to Present at the 2019 Telemed Leadership Forum

https://finance.yahoo.com/news/ceo-arcadian-telepsychiatry-services-invited-131500913.html

Director Pappajohn buys 100K shares in open market....

SOURCE: Form 4

ISSUER: MYnd Analytics Inc
SYMBOL: MYND

FILER: Pappajohn John G
TITLE: Director and Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE

3/14/19 Purchase 100,000 $1.68 $167,600


OWNERSHIP: 932,925 (Direct)


http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=12779885&ds=2

MYND gets contract with Fortune 500 Company Magellan Health!....

https://finance.yahoo.com/news/mynd-analytics-joins-magellan-healthcare-120000296.html

Telemedicine article in Barron's....

https://www.barrons.com/articles/teladoc-stock-is-a-bet-that-the-future-of-medicine-will-be-as-digital-as-shopping-banking-and-transportation-51552467601

Investor Presentation shows expanding work with Walter Reed, Canadian Govt, and US Govt.

https://www.sec.gov/Archives/edgar/data/822370/000161577419003664/s116479_ex99-1.htm

Arcadian will provide tele-EAP services for IMPACT Solutions’ customers through its provider network.

https://finance.yahoo.com/news/mynd-analytics-arcadian-telepsychiatry-services-130000593.html

Interview with MYND Chair of the Board Robin Smith...

https://cheddar.com/media/mynd-analytics-uses-a-i-to-help-treat-ptsd-and-depression

Employee clinic company Crossover Health snaps up telemedicine startup..


will same happen to MYND one day...

https://medcitynews.com/2019/02/employee-clinic-company-crossover-health-snaps-up-telemedicine-startup-sherpaa/

"Physician consultations via telemedicine are faster, cheaper and more efficient than traditional healthcare appointments."

MYND will get discovered soon!

https://www.forbes.com/sites/joeharpaz/2019/02/27/telemedicine-the-latest-futuristic-tech-prediction-from-the-jetsons-to-come-true/#19211aec7e6f

"Clearly, telepsychiatry is the wave of the future—a future that has already arrived."

quote from American Psychiatric Association blog...

https://www.psychiatry.org/psychiatrists/practice/telepsychiatry/blog/leveraging-telepsychiatry-for-population-health

Minnesota telemedicine study found a nearly seven-fold growth in visits...

For the first-of-its-kind study, Health Department and School of Public Health researchers joined together to analyze the Minnesota All Payer Claims Database for patterns of telemedicine use in Minnesota between 2010 and 2015.....

https://wctrib.com/lifestyle/health/4572250-minnesota-sees-steep-rise-telemedicine-use

MYnd Analytics Provides Business Update....

Walter Reed PEER™ trial expanding to include a large, private provider as an investigator partner

Expanding the clinical trial with the Canadian Armed Forces and University of Ottawa

https://finance.yahoo.com/news/mynd-analytics-provides-business-214351394.html

Private Equity firm buys Telemedicine Pioneer Qualcomm Life...

PE firms buying telemedicine assets shows the opportunity for growth ahead!

https://mhealthintelligence.com/news/telemedicine-pioneer-qualcomm-life-sold-to-be-renamed-capsuletech

VA expanding use of telemedicine across VA system

“VA’s telehealth capabilities are bridging the care gap for many Veterans,” VA Secretary Robert Wilkie said in a press release. “This technology gives Veterans access to the timely, quality care they deserve, without having to travel great distances to a VA facility. Time spent traveling is time away from Veterans’ jobs and families.”

https://mhealthintelligence.com/news/va-hits-telemedicine-milestone-with-1-million-video-visits-in-18

MYND recent US govt contract win shows that the VA is planning on incorporating Mynd technology into their telemedicine growth plans.

link to contract win announcement;
https://finance.yahoo.com/news/u-general-services-administration-awards-140000802.html

saw this on twitter.. telemedicine is expanding in every state it seems.

https://mhealthintelligence.com/news/arizona-lawmakers-look-to-expand-telemedicine-definition-coverage

TV news story about adoption of telepsychiatry gaining steam due in part to shortage of docs..

https://www.tmj4.com/news/local-news/patients-turn-to-telepsychiatry-in-midst-of-doctor-shortage